Page 1,485«..1020..1,4841,4851,4861,487..1,4901,500..»

Transhumanism Is Not Libertarian, It’s an Abomination – The American Conservative

Posted: August 17, 2017 at 3:47 am

Last week in TAC, Zoltan Istvan wrote about The Growing World of Libertarian Transhumanism linking the transhumanist movement with all of its featureslike cyborgs, human robots and designer babiesto the ideas of liberty. To say Mr. Istvan is mistaken in his assessment is an understatement. Transhumanism should be rejected by libertarians as an abomination of human evolution.

We begin with Mr. Istvans definition of transhumanism:

transhumanism is the international movement of using science and technology to radically change the human being and experience. Its primary goal is to deliver and embrace a utopian techno-optimistic worlda world that consists of biohackers, cyborgists, roboticists, life extension advocates, cryonicists, Singularitarians, and other science-devoted people.

The ultimate task, however, is nothing less than overcoming biological human death and to solve all humanitys problems. Throughout much of Mr. Istvans work on this issue, he seems to think these ideas are perfectly compatible with libertarianismself-evident evenso he doesnt care to elaborate for his befuddled readers.

While most advocates of liberty could be considered, as Matt Ridley coined it, rational optimistsmeaning that generally we are optimistic, but not dogmatic, about progressit is easy to get into a state in which everything that is produced by the market is good per se and every new technology is hailed as the next step on the path of progress. In this sense, these libertarians become what Rod Dreher has called Technological Men. For them, choice matters more than what is chosen. [The Technological Man] is not concerned with what he should desire; rather, he is preoccupied with how he can acquire or accomplish what he desires.

Transhumanists including Mr. Istvan are a case in point. In his TAC article he not only endorses such things as the defeat of death, but even robotic hearts, virtual reality sex, and telepathy via mind-reading headsets. Need more of his grand ideas? How about brain implants ectogenesis, artificial intelligence, exoskeleton suits, designer babies, gene editing tech? At no point he wonders if we should even strive for these technologies.

When he does acknowledge potential problems he has quick (and crazy) solutions at hand: For example, what would happen if people never die, while new ones are coming into the world in abundance? His solution to the fear of overpopulation: eugenics. It is here where we see how libertarian Mr. Istvan truly is. When his political philosophythe supposedly libertarian onecomes into conflict with his idea of transhumanism, he suddenly drops the former and argues in favor of state-controlled breeding (or, as he says, controlled breeding by non-profit organizations such as the WHO, which is, by the way, state financed). I cautiously endorse the idea of licensing parents, a process that would be little different than getting a drivers licence. Parents who pass a series of basic tests qualify and get the green light to get pregnant and raise children.

The most frustrating thing is how similar he sounds to communists and socialists in his arguments. In most articles you read by transhumanists, you can see the dream of human perfection. Mr. Istvan says so himself: Transhumanists want more guarantees than just death, consumerism, and offspring. Much More. They want to be better, smarter, strongerperhaps even perfect and immortal if science can make them that way.

Surely it is the goal of transhumanists that, in their world, the average human type will rise to the heights of an Aristotle, a Goethe, or a Marx. You can just edit the genes of the embryo in the way that they are as intelligent as Aristotle, as poetic as Goethe, and as musically talented as Mozart. There are two problems, though: First, the world would become extremely boring, consisting only of perfect human beings who are masters at everything (which perhaps would make human cooperation superfluous). Second, that quote was famously uttered by the socialist Leon Trotsky.

As Ludwig von Mises wrote sarcastically, the socialist paradise will be the kingdom of perfection, populated by completely happy supermen. This has always been the mantra of socialists, starting with utopian thinkers like Charles Fourier, but also being embraced by the scientific ones like Marx, who derived his notion of history in which communism is the final stage of humanity from Hegel. Hegel himself believed in the man-godnot in the way that God became man through Jesus, but that man could become God one day. Intentionally or not, transhumanists sound dangerously similar to that. What they would actually create would be the New Soviet Man through bio-engineering and total environmental control as the highest social goal. In other words, you get inhuman ideological tyranny taken to a whole new level.

It should be noted that sometimes transhumanists recognize this themselvesbut if they do, their solutions only make things worse (much worse). Take Adam Zaretsky as example, who says that these new human beings shouldnt be perfect: Its important to make versions of transgenic human anatomy that are not based on idealism. But his solution is frightening: The idea is that you take a gene, say for pig noses, or ostrich anuses, or aardvark tongue, and you paste that into a human sperm, a human egg, a human zygote. A baby starts to form. And: We could let it flow into our anatomy, and these peoplewho yes, are humansshould be appreciated for who and what they are, after they are forced to be born in a really radically strange way. Its no surprise that Rod Dreher calls Mr. Zaretsky a sick monster, because he truly seems to be one when it comes to his transhumanist vision. He wants to create handicapped human beings on purpose.

If this were what libertarians think should happen, it would be sad (thankfully its mostly not). As Jeff Deist notes, it is important to remember that liberty is natural and organic and comports with human action. It doesnt require a new man. Transhumanists may say that the introduction of their idea is inevitable (in Istvans words, Whether people like it or not, transhumanism has arrived) but that is not true. And in this sense, it is time for libertarians to argue against the notion of extreme transhumanism. Yes, the market has brought it about and yes, the state shouldnt prohibit it (though giving your baby a pig nose could certainly be a violation of rights), but still, one shouldnt be relativist or even nihilist about such frightening developments. It would be a shame if the libertarian maxim of Everyone should be able to do whatever one wants to (as long as no one is hurt by it) becomes Everyone should do whatever one can do just because it is possible.

Finally, it comes as no surprise that transhumanists are largely, if not all, atheists (or as Mr. Istvan says: Im an atheist, therefore Im a transhumanist. This just proves what the classical liberal historian Lord Acton talked about when he said, Progress, the religion of those who have none. In the end, transhumanism is the final step to get God out of the way. It would be the continuation of what Richard Weaver wrote about in Ideas Have Consequences: Instead of seeing nature, the world and life overall as a means to get to know God, humans in the last centuries have become accustomed to seeing the world as something that is only there for humans to take and use for their own pleasures. Transhumanism would be the final step of this process: the conquest of death.

You dont have to be religious to find this abhorrent. As we have seen, it would be the end to all religion, to human cooperation overall, in all likelihood to liberty itself, and even the good-bye to humanity. It would be the starting point of the ultimate dystopia.

Kai Weiss is an International Relations student and works for the Austrian Economics Center and Hayek Institute, two libertarianthink tanks based in Vienna, Austria.

The rest is here:
Transhumanism Is Not Libertarian, It's an Abomination - The American Conservative

Posted in Transhumanist | Comments Off on Transhumanism Is Not Libertarian, It’s an Abomination – The American Conservative

Immortality: Silicon Valley’s latest obsession ushers in the transhumanist era – South China Morning Post

Posted: August 17, 2017 at 3:47 am

Zoltan Istvan is launching his campaign to become Libertarian governor of the American state of California with two signature policies. First, hell eliminate poverty with a universal basic income that will guarantee US$5,000 per month for every Californian household for ever. (Hell do this without raising taxes, he promises.)

The next item in his in-tray is eliminating death. He intends to divert trillions of dollars into life-extending technologies robotic hearts, artificial exoskeletons, genetic editing, bionic limbs and so on in the hope that each Californian man, woman and AI (artificial intelligence) will eventually be able to upload their consciousness to the Cloud and experience digital eternity.

What we can experience as a human being is going to be dramatically different within two decades, Istvan says, when we meet at his home in Mill Valley, California. We have five senses now. We might have thousands in 30 or 40 years. We might have very different bodies, too.

I have friends who are about a year away from cutting off their arm and replacing it with a prosthetic version. And sure, pretty soon the robotic arm really will be better than a biological one. Lets say you work in construction and your buddy can lift a thousand times what you can. The question is: do you get it?

For most people, the answer to this question is likely to be, Erm, maybe Ill pass for the moment. But to a transhumanist such as Istvan, 44, the answer is, Hell, yes! A former National Geographic reporter and property speculator, Istvan combines the enthusiasm of a child whos read a lot of Marvel comics with a parodically presidential demeanour. Hes a blond-haired, blue-eyed father of two with an athletic build, a firm handshake and the sort of charisma that goes down well in TED talks.

Like most transhumanists (there are a lot of them in California), Istvan believes our species can, and indeed should, strive to transcend our biological limitations. And he has taken it upon himself to push this idea out of the Google Docs of a few Silicon Valley dreamers and into the American political mainstream.

Twenty-five years ago, hardly anybody was recycling, he explains. Now, environmentalism has conditioned an entire generation. Im trying to put transhumanism on a similar trajectory, so that in 10, 15 years, everybody is going to know what it means and think about it in a very positive way.

What were saying is that over the next 30 years, the complexity of human experience is going to become so amazing, you ought to at least see it

Zoltan Istvan

I meet Istvan at the home he shares with his wife, Lisa an obstetrician and gynaecologist with Planned Parenthood and their two daughters, six-year-old Eva, and Isla, who is three. I had been expecting a gadget-laden cyber-home; in fact, he resides in a 100-year-old loggers house built from Californian redwood, with a converted stable on the ground floor and plastic childrens toys in the yard. If it werent for the hyper-inflated prices in the Bay Area (Its sort of Facebook yuppie-ville around here, says Istvan) youd say it was a humble Californian homestead.

Still, there are a few details that give him away, such as the forbidding security warnings on his picket fence. During his unsuccessful bid for the presidency last year he stood as the Transhumanist Party candidate and scored zero per cent a section of the religious right identified him as the Antichrist. This, combined with Lisas work providing abortions, means they get a couple of death threats a week and have had to report to the FBI.

Christians in America have made transhumanism as popular as its become, says Istvan. They really need something that they can point their finger at that fulfils Revelations.

Istvan also has a West Wing box set on his mantelpiece and a small Meccano cyborg by the fireplace. Its named Jethro, after the protagonist of his self-published novel, The Transhumanist Wager (2013). And there is an old Samsung phone attached to the front door, which enables him to unlock the house using the microchip in his finger.

A lot of the Christians consider my chip a mark of the beast, he says. Im like, No! Its so I dont have to carry my keys when I go out jogging.

Istvan hopes to chip his daughters before long for security purposes and recently argued with his wife about whether it was even worth saving for a university fund for them, since by the time they reach university age, advances in artificial intelligence will mean they can just upload all the learning they need. Lisa won that argument. But hes inclined not to freeze his sperm and Lisas eggs, since if they decide to have a third child, 10 or 20 or 30 years hence, theyll be able to combine their DNA.

Even if theres a mischievous, fake-it-till-you-make-it quality to Istvan, theres also a core of seriousness. He is genuinely troubled that we are on the verge of a technological dystopia that the mass inequalities that helped fuel US President Donald Trumps rise will only worsen when the digital revolution really gets under way. And he despairs of the retrogressive bent of the current administration: Trump talks all the time about immigrants taking jobs. Bulls**t. Its technology thats taking jobs. We have about four million truck drivers who are about to lose their jobs to automation. This is why capitalism needs a basic income to survive.

And hes not wrong in identifying that emerging technologies such as AI and bio-enhancement will bring with them policy implications, and its probably a good idea to start talking about them now.

Stephen Hawkings question to China: will AI help or destroy the human race?

Certainly, life extension is a hot investment in Silicon Valley, whose elites have a hard time with the idea that their billions will not protect them from an earthly death. Google was an early investor in the secretive biotech start-up Calico, the California Life Company, which aims to devise interventions that slow ageing and counteract age-related diseases. Billionaire venture capitalist Peter Thiel has invested millions in parabiosis: the process of curing ageing with transfusions of young peoples blood.

Another biotech firm, United Therapeutics, has unveiled plans to grow fresh organs from DNA. Clearly, it is possible, through technology, to make death optional, the firms founder, Martine Rothblatt, told a recent gathering of the National Academy of Medicine in Los Angeles.

In attendance were Google co-founder Sergey Brin, vegan pop star Moby and numerous venture capitalists. Istvan fears that unless we develop policies to regulate this transition, the Thiels of this world will soon be hoarding all the young blood for themselves.

Clearly, it is possible, through technology, to make death optional

Martine Rothblatt

Istvan was born in Oregon in 1973, the son of Hungarian immigrants who fled Stalins tanks in 1968. He had a comfortable middle-class upbringing his mother was a devout Catholic and sent him to Catholic school and an eye for a story. After graduating from Columbia University, he embarked on a solo round-the-world yachting expedition, during which, he says, he read 500 works of classic literature. He spent his early career reporting for the National Geographic channel from more than 100 countries, many of them conflict zones, claiming to have invented the extreme sport of volcano boarding along the way.

One of the things he shares in common with Americas current president is a fortune accrued from real estate. While he was making films overseas in the noughties, his expenses were minimal, so he was able to invest all of his pay cheques in property.

AlphaGos China showdown: Why its time to embrace artificial intelligence

So many people in America were doing this flipping thing at the time, explains Istvan. I realised very quickly, Wow! I could make enough money to retire. It was just quite easy and lucrative to do that.

At his peak, he had a portfolio of 19 fixer-upper houses, most of which he managed to sell before the crash of 2008. He now retains nine as holiday rentals and uses the proceeds to fund his political campaigns (he is reluctant to name his other backers). Still, he insists hes not part of the 1 per cent; the most extravagant item of furniture is a piano, and his groceries are much the same as you find in many liberal, middle-class Californian households.

Istvan cant think of any particular incident that prompted his interest in eternal life, other than perhaps a rejection of Catholicism.

Fifty per cent of me thinks after we die we get eaten by worms, and our body matter and brain return unconsciously to the cosmos [] The other half subscribes to the idea that we live in a holographic universe where other alien artificial intelligences have reached the singularity, he says, referring to the idea, advanced by Google engineer Ray Kurzweil, that pretty soon we will all merge with AI in one transcendental consciousness.

However, when Istvan first encountered transhumanism, at university via an article on cryonics (the practice of deep-freezing the recently dead in the hope that they can be revived at some point), he was sold. Within 90 seconds, I realised thats what I wanted to do in my life.

After a near-death experience in Vietnam he came close to stepping on a landmine Istvan decided to return to America and make good on this vow. I was nearing 30 and Id done some great work, but after all that time Id spent in conflict zones, seeing dead bodies, stuff like that, I thought it would be a good time to dedicate myself to conquering death.

He spent four years writing his novel, which he proudly claims was rejected by more than 600 agents and publishers. Its a dystopian story that imagines a Christian nation outlawing transhumanism, prompting all the billionaires to retreat to an offshore sea-stead where they can work on their advances undisturbed (Thiel has often threatened to do something similar).

Istvan continued to promote transhumanism by writing free columns for Huffington Post and Vice, chosen because they have strong Alexa rankings (ie, they show up high in Google search results).

I wrote something like 200 articles, putting transhumanism through the Google algorithm again and again, he says. I found it a very effective way to spread the message. I covered every angle that I could think of: disability and transhumanism; LGBT issues and transhumanism; transhumanist parenting.

Hes proud to say hes the only mainstream journalist who is so devoted to the cause. A lot of people write about transhumanism, but I think Im the only one who says, This is the best thing thats ever happened!

Why your biological age may hold the key to reversing the ageing process

Istvans presidential campaign was an attempt to take all of this up a level. It sounds as if he had a lot of fun. He toured Rust Belt car parks and Deep South mega-churches in a coffin-shaped immortality bus inspired by the one driven by Ken Kesey and his Merry Pranksters to promote LSD in the 1960s.

His platform Make America Immortal Again earned a fair amount of publicity, but Americans seemed ill-prepared for such concepts as the AI imperative (the idea that the first nation to create a true AI will basically win everything, so America had better be the first) and the singularity. At one point, he and his supporters were held at gunpoint by some Christians in Alabama.

The experience taught him a salutary lesson: unless you are a billionaire, it is simply impossible to make any kind of dent in the system. Hence his defection to the Libertarian Party, which vies with the Greens as the third party in American politics. Every town I go to, theres a Libertarian meet-up. With the Transhumanists, Id have to create the meet-up. So theres more to work with.

The Libertarian presidential candidate, Gary Johnson, received 3.27 per cent of the votes last year, including half a million votes in California. About seven or eight million are likely to vote in the California governor race, in which context, half a million starts to become a lot of votes, Istvan explains.

His own politics are somewhere between Hillary Clinton and Bernie Sanders, he admits, and he has a hard time converting the right wing of his new party to causes such as basic income. (The general spirit of libertarian America is, Hands off!) But he believes transhumanism shares enough in common with libertarianism for the alliance to be viable; the core precepts of being able to do what you like as long as you dont harm anyone else are the same. And the gubernatorial campaign serves as a primary for the 2020 presidential election, when he believes the Libertarian candidate will have a feasible chance of participating in the television debates.

But whats wrong with death? Dont we need old people to die to make space for new people? And by extension, we need old ideas and old regimes to die, too. Imagine if William Randolph Hearst or Genghis Khan were still calling the shots now. And imagine if Mark Zuckerberg and Vladimir Putin were doing so in 200 years. Innovation would cease, the species would atrophy, everyone would get terribly bored. Isnt it the ultimate narcissism to want to live forever?

Istvan does concede that transhumanism is a very selfish philosophy. However, he has an answer for most of the other stuff.

Im a believer in overpopulation Ive been to Delhi and its overcrowded, he says. But if we did a better job of governing, the planet could hold 15 billion people comfortably. Its really a question of better rules and regulations.

And when discussing the desirability of eternal life, he turns into a sort of holiday rep for the future.

What were saying is that over the next 30 years, the complexity of human experience is going to become so amazing, you ought to at least see it, Istvan says. A lot of people find that a lot more compelling than, say, dying of leukaemia.

Still, it comes as little surprise that hes finding live for ever an easier sell than give money to poor people in 21st-century America.

I cant imagine basic income not becoming a platform in the 2020 election, he insists. And if not then, at some point, someone is going to run and win on it. The Republicans should like it because it streamlines government. The Democrats should like it because it helps poor people. Right now, Americans dont like it because it sounds like socialism. But it just needs a little reframing.

Basic-income experiments are already under way in parts of Canada, Finland and the Netherlands, but how would he fund such an idea in the US? He cant raise taxes libertarians hate that. And he doesnt want to alienate Silicon Valley.

If we did a better job of governing, the planet could hold 15 billion people comfortably

Zoltan Istvan

How do you tell the 1 per cent youre going to take all this money from them? It wouldnt work, he says. They control too many things. But Istvan has calculated that 45 per cent of California is government-controlled land that the state could monetise.

A lot of environmentalists are upset at me for that, saying, Woah, Zolt, you want to put a shopping mall in Yosemite? Well, the reality is that the poor people in America will never be able to afford to go to Yosemite. Im trying to be a diplomat here.

And he insists that if Americans miss those national parks when theyve been turned into luxury condos and Taco Bells, theyll be able to replenish them some day if they want.

Theres nanotechnology coming through that would enable us to do that, Istvan argues. We have GMOs [genetically modified organisms] that can regrow plants twice as quick. In 50 or 100 years, were not even going to be worried about natural resources.

Such is his wager that exponential technological growth is around the corner and we may as well hurry it along, because its our best chance of clearing up the mess weve made of things thus far.

The safety of genetically-modified crops is backed by science

Didnt the political developments of 2016 persuade him that progress can be slow and sometimes go backwards? Actually, Istvan argues that what were witnessing are the death throes of conservatism, Christianity, even capitalism.

Everyone says the current pope is the best one weve had for ages, that hes so progressive and whatever. Actually, Catholicism is dying, says Istvan. Nobodys giving it any money any more, so the pope had better moderate its message. As for capitalism, all of this nationalism and populism are just the dying moments.

Its a system that goes against the very core of humanitarian urges. And while its brought us many wonderful material gains, at some point we can say, Thats enough. In the transhumanist age, we will reach utopia. Crime drops to zero. Poverty will end. Violence will drop. At some point, we become a race of individuals who are pretty nice to each other.

But now weve talked for so long that Istvan needs to go and pick up his daughters from childcare. He insists that I join him. What do his family make of all of this?

My wife is a bit sceptical of a lot of my timelines, he says. Lisa comes from practical Wisconsin farming stock, and its a fair bet that her work with Planned Parenthood keeps her pretty grounded. They met on dating website match.com. Does she believe in all this stuff?

I dont want to say shes not a transhumanist, he says, but I dont think shed cryogenically freeze herself tomorrow. I would. Im like, If you see me dying of a heart attack, please put me in a refrigerator. She thinks thats weird.

We arrive at the community centre where Istvans daughters are being looked after. They come running out in summer dresses, sweet and sunny and happy to be alive. Both of them want to be doctors when they grow up, like their mum.

The Times/The Interview People

Here is the original post:
Immortality: Silicon Valley's latest obsession ushers in the transhumanist era - South China Morning Post

Posted in Transhumanist | Comments Off on Immortality: Silicon Valley’s latest obsession ushers in the transhumanist era – South China Morning Post

Molecular Medicine Research – Wake Forest School of Medicine

Posted: August 17, 2017 at 3:46 am

The Section on Molecular Medicinefocuses on performing cutting-edge research in cellular and molecularmechanisms of human disease and supports graduate and postgraduate leveleducational programs within the Department of Internal Medicine. The Sectionserves as the administrative home for the largest PhD graduate program(Molecular Medicine and Translational Science) in the Biomedical Sciences atWake Forest University and an NIH-sponsored institutional predoctoral trainingprogram (T-32) in Integrative Lipid Sciences, Inflammation, and ChronicDiseases.

A major goal of the section is toserve as a nidus for translational research by providing an environment whereclinical and basic science faculty interact to make new discoveries and toeducate future scientists.

The section consists of ten (10) primary faculty members and one (1) Emeritus faculty member who use cellular and molecular approaches to gain abetter understanding of the basic mechanisms underlying several chronic humanconditions including: asthma, atherosclerosis, hepatosteatosis, obesity andinsulin resistance, autoimmunity, and age-related pathology (arthritis,Alzheimers disease).

A particular research focus isthe role of inflammation in the pathogenesis of acute and chronic humandiseases. Faculty research strengths are in areas of cell signaling, cellbiology, proteomics, regulation of gene expression, and the use of genetically-modifiedmouse models of human disease. The research in the section is supported bygrants from the NIH, from the Department of Defense, from foundations including the Avon Foundation and theAmerican Heart Association, and from partnerships with industry.

The section also provides acenter for laboratory research training and education in translational researchfor medical students, residents, and postdoctoral fellows includingsubspecialty fellows in the Department of Internal Medicine. A seminar seriesis held weekly in conjunction with the graduate program in Molecular Medicineand Translation Science.

John S. Parks, PhDProfessor of Internal Medicine, Biochemistry, and Translational ScienceChief, Section on Molecular Medicine

Molecular Medicine Journal Club

Faculty News

Originally posted here:
Molecular Medicine Research - Wake Forest School of Medicine

Posted in Molecular Medicine | Comments Off on Molecular Medicine Research – Wake Forest School of Medicine

MS in Molecular Medicine – Drexel University College of …

Posted: August 17, 2017 at 3:46 am

The Master of Science in Molecular Medicine (MMED) program provides training in the academic, research and entrepreneurial aspects of the biomedical sciences with an emphasis on translational research in the development of therapeutics and vaccines.

Participation in the program will provide enhanced educational credentials through a flexible curriculum, with most classes offered in the early evening to maximize accessibility. Classes can be attended at two Drexel University College of Medicine locations: Center City and Queen Lane Campuses in Philadelphia. State-of-the-art videoconferencing provides real-time interactive learning at both locations.The program now can also be completed online, with all required courses and many elective courses available.

The Master of Science in Molecular Medicine program is designed to provide academic and practical biotechnological knowledge in translational research, particularly in the areas of molecular therapeutics and vaccine development.

If you prefer an online learning experience, you can still earn a Drexel master's degree in the field of molecular medicine. The online Master of Science in Molecular Medicine program features the same curriculum, flexibility, course content, and instructors as the traditional, face-to-face degree program.

Learn more about the online Master of Science in Molecular Medicine program!

In addition to broad geographic access, the curriculum provides flexibility in content and course load. Most students will complete the program in two years through completion of required courses and electives selected from two menus: research theory and laboratory research. The research experience can be in an academic environment or a company setting, as best fits the individual student's goals and interests.Some students may opt to complete the program on a part-time basis, taking up to four years. In either sequence, no dissertation is required. Program directors and course faculty will work closely with each student to best achieve his or her specific goals.

Learn more about the curriculum

The molecular medicine program is ideally suited for enhancing the scientific credentials of the following groups:

Read the original post:
MS in Molecular Medicine - Drexel University College of ...

Posted in Molecular Medicine | Comments Off on MS in Molecular Medicine – Drexel University College of …

Master of Science (MSc) in Molecular Medicine – NTNU

Posted: August 17, 2017 at 3:46 am

International students are encouraged to attend NTNU'sOrientation Week14 - 20 August 2017.

OnMonday 21 August at 10:15there will be a welcome meeting for all new master's students at the Faculty of Medicine and Health Sciences. This meeting takes place in auditorium KA12 in theKnowledge Centre at Campus ya.

After the welcome meeting (Monday 21 August at 12:00)there will be an orientation meeting for the MSc in Molecular Medicine. This meeting takes place in room Ls42 in the Laboratory Centre at Campus ya. It iscompulsory to attendthis meeting.

The field of molecular medicine is often referred to as "tomorrow's medicine". It aims to provide a molecular understanding of how normal cellular processes change, fail or are destroyed by disease. The purpose of the MSc programme is to develop knowledge and skills in cellular and molecular biology. These have applications in both research and practical clinical work, and will contribute to an increased understanding of processes, diagnostics and treatment of diseases.

The application deadline for for applicants from non-EU/non-EEA students is 1 December. The application deadline for students from EU/EEA countries is 1 March. You submit your application electronically.

The MSc in Molecular Medicine qualifies graduates for a wide range of careers, including practical clinical work and technical executive positions in hospital laboratories, and positions in pharmaceuticals and MedTech/BioTech companies.

The MSc is a two-year, full-time programme starting in the autumn semester. There are two main components: a master's thesis worth 60 credits, and theoretical and methodological courses totalling a further 60 credits.

Contact one of our student counsellors if you have any questions about the MSc programme. Email: lbk-post@medisin.ntnu.no / Telephone: +47 72 82 07 00

Continue reading here:
Master of Science (MSc) in Molecular Medicine - NTNU

Posted in Molecular Medicine | Comments Off on Master of Science (MSc) in Molecular Medicine – NTNU

Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for … – Markets Insider

Posted: August 17, 2017 at 3:46 am

URBANDALE, Iowa, Aug. 16, 2017 /PRNewswire/ --Spotlight Innovation Inc. (OTCQB: STLT) today announced that the Company has entered into a Sponsored Research Agreement with Indiana University to support research directed by Elliot Androphy, M.D., aimed at developing safe and effective drugs to treat patients with spinal muscular atrophy (SMA). Dr. Androphy is a member of Spotlight Innovation's Scientific Advisory Board and a co-inventor of STL-182, the Company's lead product candidate for SMA.

Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development, commented, "Dr. Androphy is a prolific researcher and highly-respected thought leader. We are privileged to work with him to develop novel therapies for SMA."

Dr. Androphy is the Chair of the Department of Dermatology of Indiana University School of Medicine and has published widely in high-impact journals including Science, Nature, EMBO Molecular Medicine, Human Molecular Genetics, Journal of Virology, and Molecular Cell. He served as Vice Chair for Research of the Department of Medicine and Director of the M.D./Ph.D. Program at the University of Massachusetts Medical School where his lab characterized the disease-causing mechanism of alternative splicing of the SMN2 gene. At Indiana University School of Medicine, Dr. Androphy has used a novel, cell-based high throughput screen for compounds that increase levels of the SMN protein. This work has led to the identification of pre-clinical drug candidates for SMA.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. Whenscientifically significantbenchmarkshave been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit http://www.spotlightinnovation.com or follow us on http://www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize various product candidates, including STL-182, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of STL-182; the inability to hire appropriate staff to develop STL-182; unforeseen technical difficulties in developing STL-182; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

View original content with multimedia:http://www.prnewswire.com/news-releases/spotlight-innovation-enters-into-sponsored-research-agreement-with-indiana-university-to-develop-new-therapies-for-spinal-muscular-atrophy-300505024.html

SOURCE Spotlight Innovation Inc.

Continued here:
Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for ... - Markets Insider

Posted in Molecular Medicine | Comments Off on Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for … – Markets Insider

Cancer Treatment Centers of America and Foundation Medicine Join Forces to Advance Precision Cancer Treatment – Markets Insider

Posted: August 17, 2017 at 3:46 am

CAMBRIDGE, Mass., Aug. 15, 2017 /PRNewswire/ --Cancer Treatment Centers of America (CTCA) and Foundation Medicine today announced a new element to their longstanding partnership to increase awareness of advancements in genomic testing and precision medicine in oncology. The educational initiative directed toward physicians, other caregivers and patients will highlight the importance of integrating comprehensive genomic testing of solid tumors early in an individual's care plan as a model to inform personalized care and improve clinical outcomes for individuals with cancer.

"Precision cancer treatment using advanced genomic testing is changing the science of cancer care," said Maurie Markman, M.D., President of Medicine & Science at CTCA. "As oncologists, we have an obligation to the patients we serve to keep pace with, and, whenever possible, lead the way in the application of the latest diagnostic tools that may help inform treatment decisions. Our partnership with Foundation Medicine empowers our physicians to customize treatment plans according to the individual patient's clinical profile right down to the molecular level, and therefore furnish care in a much more comprehensive and effective manner."

The partnership brings together CTCA, a national network of five cancer treatment hospitals at the forefront of delivering precision cancer treatment to address individual patients' unique treatment needs, and Foundation Medicine, a leader in molecular information that offers a suite of comprehensive genomic profiling (CGP) assays that identifies the molecular alterations in an individual's cancer and matches them with potentially relevant targeted therapies, including immunotherapies.

Through their shared patient-centered philosophy, CTCA and Foundation Medicine will educate the medical community about the successful approach CTCA is using to incorporate FoundationOne for solid tumors into clinical care. Specifically, the educational initiative will feature several patients with cancer, chronicling each person's journey from cancer diagnosis to tumor profiling to treatment. Through this case-based approach, the program aims to provide insights into precision medicine treatment approaches based on an individual's unique cancer, including the selection of targeted therapies, appropriate clinical trials and responses to immunotherapy.

"Precision medicine, and a move to a more personalized, targeted approach to cancer care, is becoming ever more ubiquitous as the published data continues to validate this approach as leading to better clinical outcomes for patients," said Vincent Miller, M.D., Chief Medical Officer for Foundation Medicine. "As such, it's critical that every stakeholder in a patient's care planphysician, patient and care teamis knowledgeable about the benefits of genomic profiling, and importantly, that they have the right tools at the ready to implement such an approach. We applaud CTCA leadership in this area and we're delighted to collaborate with them on this educational initiative."

To learn more about genomics and precision cancer treatment, visit cancercenter.com. To learn more about genomic testing and FoundationOne, visit FoundationMedicine.com.

About Cancer Treatment Centers of AmericaCancer Treatment Centers of America Global, Inc. (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-informed supportive therapies designed to help patients physically and emotionally by enhancing their quality of life while managing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Reflecting our patient-centered approach to cancer care, our patient satisfaction scores consistently rank among the highest in the country for cancer care providers, and CTCA is also rated one of the most admired hospital systems in the country in national consumer surveys. For more information, visit cancercenter.com, Facebook.com/cancercenter and Twitter.com/cancercenter.

About Foundation MedicineFoundation Medicine(NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.Foundation Medicine'smolecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visithttp://www.FoundationMedicine.comor followFoundation Medicineon Twitter (@FoundationATCG). Foundation Medicineand FoundationOne are registered trademarks ofFoundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the objectives of any educational initiatives between CTCA and Foundation Medicine; the importance of integrating comprehensive genomic testing of solid tumors early in an individual's care plan to improve clinical outcomes for individuals with cancer; and the value and performance capabilities of Foundation Medicine's comprehensive genomic profiling assays. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk thateducational initiatives are not developed or launched in the anticipated manner; Foundation Medicine'sCGP andservices will not be able to identify genomic alterations in the same manner as prior clinical data or prior experience; and the risks described under the caption "Risk Factors" inFoundation Medicine'sAnnual Report on Form 10-K for the year endedDecember 31, 2016, which is on file with theSecurities and Exchange Commission, as well as other risks detailed inFoundation Medicine'ssubsequent filings with theSecurities and Exchange Commission.All information in this press release is as of the date of the release, andFoundation Medicineundertakes no duty to update this information unless required by law.

Contact: Michael MyersCancer Treatment Centers of America rel="nofollow">michael.myers@ctca-hope.com 561-923-3179

Lee-Ann MurphyFoundation Medicine 617-245-3077 rel="nofollow">pr@foundationmedicine.com

View original content with multimedia:http://www.prnewswire.com/news-releases/cancer-treatment-centers-of-america-and-foundation-medicine-join-forces-to-advance-precision-cancer-treatment-300504156.html

SOURCE Cancer Treatment Centers of America

Read more:
Cancer Treatment Centers of America and Foundation Medicine Join Forces to Advance Precision Cancer Treatment - Markets Insider

Posted in Molecular Medicine | Comments Off on Cancer Treatment Centers of America and Foundation Medicine Join Forces to Advance Precision Cancer Treatment – Markets Insider

A New Method of 3D Printing Living Tissues – Technology Networks

Posted: August 17, 2017 at 3:46 am

Scientists at the University of Oxford have developed a new method to 3D-print laboratory-grown cells to form living structures.

The approach could revolutionise regenerative medicine, enabling the production of complex tissues and cartilage that would potentially support, repair or augment diseased and damaged areas of the body.

Printing high-resolution living tissues is hard to do, as the cells often move within printed structures and can collapse on themselves. But, led by Professor Hagan Bayley, Professor of Chemical Biology in Oxfords Department of Chemistry, the team devised a way to produce tissues in self-contained cells that support the structures to keep their shape.

The cells were contained within protective nanolitre droplets wrapped in a lipid coating that could be assembled, layer-by-layer, into living structures. Producing printed tissues in this way improves the survival rate of the individual cells, and allowed the team to improve on current techniques by building each tissue one drop at a time to a more favourable resolution.

To be useful, artificial tissues need to be able to mimic the behaviours and functions of the human body. The method enables the fabrication of patterned cellular constructs, which, once fully grown, mimic or potentially enhance natural tissues.

Dr Alexander Graham, lead author and 3D Bioprinting Scientist at OxSyBio (Oxford Synthetic Biology), said: We were aiming to fabricate three-dimensional living tissues that could display the basic behaviours and physiology found in natural organisms. To date, there are limited examples of printed tissues, which have the complex cellular architecture of native tissues. Hence, we focused on designing a high-resolution cell printing platform, from relatively inexpensive components, that could be used to reproducibly produce artificial tissues with appropriate complexity from a range of cells including stem cells.

The researchers hope that, with further development, the materials could have a wide impact on healthcare worldwide. Potential applications include shaping reproducible human tissue models that could take away the need for clinical animal testing.

Over the coming months they will work to develop new complementary printing techniques, that allow the use of a wider range of living and hybrid materials, to produce tissues at industrial scale. Dr Sam Olof, Chief Technology Officer at OxSyBio, said: There are many potential applications for bioprinting and we believe it will be possible to create personalised treatments by using cells sourced from patients to mimic or enhance natural tissue function. In the future, 3D bio-printed tissues maybe also be used for diagnostic applications for example, for drug or toxin screening.

Dr Adam Perriman from the University of Bristols School of Cellular and Molecular Medicine, added: The bioprinting approach developed with Oxford University is very exciting, as the cellular constructs can be printed efficiently at extremely high resolution with very little waste. The ability to 3D print with adult stem cells and still have them differentiate was remarkable, and really shows the potential of this new methodology to impact regenerative medicine globally.

This article has been republished frommaterialsprovided by the University of Oxford. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Graham, A. D., Olof, S. N., Burke, M. J., Armstrong, J. P., Mikhailova, E. A., Nicholson, J. G., . . . Bayley, H. (2017). High-Resolution Patterned Cellular Constructs by Droplet-Based 3D Printing. Scientific Reports, 7(1). doi:10.1038/s41598-017-06358-x

Read the original post:
A New Method of 3D Printing Living Tissues - Technology Networks

Posted in Molecular Medicine | Comments Off on A New Method of 3D Printing Living Tissues – Technology Networks

What can genetic testing really tell you? – Popular Science

Posted: August 17, 2017 at 3:46 am

Once difficult and expensive even for the most technologically advanced labs, genetic testing is fast becoming a cheap and easy consumer product. With a little spit and 200 dollars, you can find out your risk for everything from cystic fibrosis to lactose intolerance.

But its important to remember that not all genetic tests are created equal. And even the best clinical genetic test, carried out in a medical lab under a doctor's supervision, isn't perfectgenes are important, but they don't seal your fate.

Genetic tests are diagnostic, so anyone who is curious about their health can get one done. But they're more informative if you think you might be at risk for a genetic disorder.

Heavy-duty genetic tests have been used as a clinical tool for almost half a centurylong before 23andMe and Ancestry.com began offering direct-to-consumer tests. Lets say that many women in your family have had breast cancer. You can get a genetic test to see if you may have inherited an abnormal version of the BRCA gene, known to increase your risk for breast cancer.

Heidi Rehm, associate professor of pathology at Harvard Medical School, is the director of the Laboratory for Molecular Medicine, where patients get tested for diseases that can be traced to specific genetic roots. She says it is most common for people to get tested when they either suspect or know that they have a genetic disease; it may have affected multiple people in their family or they could show symptoms of something widely known to be genetic, like sickle cell anemia. For these people, genetic tests can provide a much-needed explanation for an illness and help doctors determine the best course of treatment. Babies are often tested for genetic diseases, either while they are still fetuses or shortly after birth.

Others get genetic tests if they and their partner both have family histories of an inherited diseaseeven if they dont have the disease themselves. For example, cystic fibrosis is linked to one particular gene, but you have to inherit the abnormal version of the gene from both your parents to get the disease. If you only inherit one copy, you may never knowyou wont display any of the symptoms. But if you and your partner both carry one copy of the faulty gene, your child could still inherit two copies. Genetic tests can forewarn you of that possibility.

But Rehm says there has been a recent trend of healthy people getting tested to predict whether theyll get certain diseases. I do think there are settings where predictive genetic testing is incredibly important and useful, Rehm says; for example, knowing that youre at risk for breast cancer gives you the opportunity for early intervention (remember when Angelina Jolie got a double mastectomy upon finding out she had a mutated BRCA gene?)

But Rehm also points out that genetic tests may not be as straightforward as they seem. For example, some genes are thought to increase risk of getting a certain disease, but it might only happen if you have specific family history, or you might be able to reduce your risk with lifestyle changes. So remember that a genetic test isnt the final verdictthere are other factors at play too.

Not entirelyits scope is limited. For starters, not all diseases are caused by genes. Plenty of conditions stem from environmental and lifestyle factors; they may interact with your genes, but the external factors are the real trigger.

But even if a disease is caused solely by faulty instructions written in your genes, you wont necessarily be able to test for it. Thats because genetic tests are mainly used for diseases that are penetrant, a term that scientists use to describe a strong connection between having a certain gene (or multiple genes) and getting a disease.

Genetic tests are surprisingly simple on the surface. All thats required of you is a small sample of cells, like a blood sample or saliva (which doesnt have DNA itself, but picks up cheek cells during its journey out of your mouth). It get sent to a lab where sequencing machines match up small pieces of synthetic DNA with your DNA to figure out the overall sequence.

Once they have your sequence, geneticists can compare it with "normal" or disease-causing sequences. In the end, they might give you a yes or no answer, or sometimes youll get a probabilitya measure of how much your genes increase your risk of developing the disease. Then, its up to your doctor to figure out what these genes (in combination with your lifestyle, family history and other risk factors) mean for your health.

With penetrant diseases, theres a very, very high ability to explain the disease, Rehm says. For example, the breast cancer-related gene BRCA1 can give you a 60 percent chance of getting breast cancer (in Jolies case, with her family history, the risk was 87 percent.)

This makes genetic tests better at detecting so-called rare diseases, says Steven Schrodi, associate research scientist at the Marshfield Clinic Research Institutes Center for Human Genetics, but theyre less useful when it comes to more common diseases, like heart disease or diabetes. Genetics can increase your likelihood of getting these disease, but scientists still dont know quite how much. Part of the problem is that there may be dozens or hundreds of genes responsible for these diseases, Schrodi says.

We have an incomplete understanding of why people get diseases, Schrodi says. A large part of it hinges on how we define diseases. Perhaps physicians have inadvertently combined multiple diseases together into a single entity.

Consumer genetic teststhe ones where you send in samples from homesometimes claim to test for these more complex traits, but be careful: Their results might not be very medically relevant, Rehm says. If they tell you that your genes make you twice as likely to develop diabetes, for example, that's a marginal increase that doesn't significantly affect your risk, especially when you take into account lifestyle factors.

Genes do seem to play a role in determining lifespan. After all, some family reunions stretch from great-great-grandparents all the way down to infants. Scientists have studied centenarianspeople who lived to be 100 years oldand found that people with certain versions of genes involved in repairing DNA tend to live longer.

This makes sense because aging leaves its mark on your DNA. Environmental factors can damage DNA, and even the routine chore of replicating cells can introduce errors as the three billion units of your DNA are copied over and over. Long-lived individuals have different sequences that seem to make their cells better at keeping DNA in mint condition.

But figuring out your expiration date is more complex than just testing for a few genes, says Jan Vijg, professor of genetics at Albert Einstein College of Medicine. In theory, you could design a test that looks at specific genes that might measure your risk for developing Alzheimers Disease or other age-related diseases, or your risk for aging quickly. To some extent, yes: Biomarkers will tell you something about your chances of living a long life, Vijg says. Still, that will only work if you live a careful life. And that means no accidents, infections, or cancers.

Aging also affects the exposed ends of your DNA, called "telomeres." DNA is stored as chromosomes, those X-like structures that you may have seen in biology textbooks. The most vulnerable parts of the chromosome are the chromosomes tips, which get shorter as you age because they arent properly replicated. But while telomere length might let you compare your DNA now with your DNA from a decade ago, you cant compare your own telomeres with other peoples telomeres. Theres a lot of variation between individuals, Vijg says. Some of us are just old souls (on the genomic level, that is.)

The methylation test, which looks at how the presence of small chemical groups attached to your DNA changes as you age, might be a better bet. A study at UCLA showed that changes were slower in longer-lived people. But Vijg is hesitant: I would not put my hopes on that as a marker to predict when exactly youre going to die.

For now, just enjoy your life, because you cant predict death. And if you decide to unlock the secrets of your DNA with an at-home test, don't take those results for more than their worth.

More:
What can genetic testing really tell you? - Popular Science

Posted in Molecular Medicine | Comments Off on What can genetic testing really tell you? – Popular Science

Testosterone therapy improves sexual functions – India New England

Posted: August 17, 2017 at 3:45 am

New York Long-term testosterone replacement therapy improves both sexual and urinary functions as well as quality of life for men suffering from a condition due to deficiency of the hormone, according to a study.

Testosterone is a steroid hormone involved in the regulation of sexual function, urinary health and metabolism as well as a number of other critical functions.

For most men, testosterone concentration declines slowly with age and may not cause immediate major symptoms.

However, some men may experience a host of signs and symptoms constituting a clinical condition called Testosterone Deficiency (TD), or male hypogonadism, which is attributed to insufficient levels of testosterone.

Office Portrait of MED Prof. Dr. Abdulmaged TraishPhoto by Vernon Doucette for Boston University Photography

As a result, they experience symptoms as varied as erectile dysfunction, low energy, fatigue, depressed mood and an increased risk of diabetes.

The study, published in the Journal of Urology, investigated the effects of long-term testosterone replacement therapy on urinary health and sexual function as well as quality of life in men with diagnosed, symptomatic testosterone deficiency.

More than 650 men in their 50s and 60s enrolled in the study, some with unexplained testosterone deficiency and others with known genetic and auto-immune causes for their hypogonadism.

It is thought that testosterone treatment in men may increase prostate size and worsen lower urinary tract symptoms, said Abdulmaged Traish, Professor of Urology at Boston University School of Medicine in the US.

However, the researchers discovered that despite increased prostate size in the group that received testosterone therapy, there were fewer urinary symptoms such as frequent urination, incomplete bladder emptying, weak urinary stream and waking up at night to urinate.

In addition to these subjective improvements, the researchers conducted objective testing that showed that those men treated with testosterone emptied their bladders more fully.

Finally, testosterone treatment also increased the scores patients received on assessments of their erectile/sexual health and general quality of life, the study said.

Related

Read the original post:
Testosterone therapy improves sexual functions - India New England

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone therapy improves sexual functions – India New England

Page 1,485«..1020..1,4841,4851,4861,487..1,4901,500..»